Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

The main aim of this study is to investigate the possible effect of GLPG4716 on the pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety and tolerability

Accepts healthy volunteers
  • 0 views
  • 11 Nov, 2021
  • 1 location
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 23 views
  • 24 Mar, 2022
  • 5 locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

pamrevlumab
carbon monoxide
nintedanib
diffusion capacity of the lung for carbon monoxide
idiopathic pulmonary fibrosis
  • 736 views
  • 30 Apr, 2022
  • 129 locations
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.

pamrevlumab
carbon monoxide
nintedanib
diffusion capacity of the lung for carbon monoxide
idiopathic pulmonary fibrosis
  • 61 views
  • 05 May, 2022
  • 89 locations
Immunosuppressant Combined With Pirfenidone in CTD-ILD

A prospective cohort study was used to observe the efficacy and safety of different immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong University for

dyspnea
pirfenidone
rheumatism
progressive systemic sclerosis
immunosuppressive
  • 0 views
  • 24 Jun, 2021
  • 1 location
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease (TOP-CKD)

will use these measures to evaluate pirfenidone as a promising potential new treatment for patients with kidney disease.

heart failure
renal failure
cardiovascular disease
nephropathy
  • 0 views
  • 16 May, 2022
  • 2 locations
Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in

  • 11 views
  • 09 Jan, 2022
  • 3 locations
Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics

To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial program

caffeine
Accepts healthy volunteers
glomerular filtration rate
  • 0 views
  • 21 Apr, 2022
  • 1 location
Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis

nintedanib and pirfenidone. The antifibrotic properties of pirfenidone have raised great expectations and many clinical trials are currently being carried out in other lung diseases that cause fibrosis

  • 0 views
  • 25 Mar, 2022
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia (PINCER)

The antifibrotic agents, namely pirfenidone and nintedanib have been found to be effective in the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib has also been found to be effective

  • 38 views
  • 11 May, 2022
  • 1 location